Natera Inc (NTRA) jumped 3.51% after Japan's regulatory authority approved its Signatera test as a companion diagnostic for muscle-invasive bladder cancer, creating a new growth opportunity for the company. The move is supported by strong bullish momentum, with the stock trading well above all major moving averages and momentum signals reinforcing upward conviction.
Highlights
- Natera secured Japanese regulatory approval for its Signatera test in muscle-invasive bladder cancer, targeting a market launch in early 2027.
- Natera reported a 37.7% year-over-year revenue increase to $752.75 million and raised 2026 guidance.
- Shares of Natera trade in a strong uptrend with robust bullish technical signals, expected to consolidate within a $386.66 to $422.33 range.
Japanese entry and director share sale shape market outlook
Natera received approval from Japan's Pharmaceuticals and Medical Devices Agency for the Signatera test in muscle-invasive bladder cancer, unlocking entry into the Japanese market with a launch planned for the first half of 2027. In the latest quarter, Natera reported a 37.7% revenue increase to $752.75 million and raised its guidance for 2026. Director Jonathan Sheena also filed to sell 21,064 shares valued at approximately $8.16 million in September 2026.
Technical strength as overbought signals flag reversal risk
Natera is trading well above its 20-day, 50-day, and 200-day moving averages ($343.15, $311.03, and $242.87 respectively), reinforcing bullish momentum across all timeframes. The sustained uptrend is further supported by the Ichimoku Kijun baseline ($352.62) and the bullish MA-50 vs MA-200 alignment, with the near-term ceiling at $408.51 and support at the $394.86 near-term floor. Momentum gauges remain robust: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both give buy signals, reflecting strong directional conviction. The Relative Strength Index (RSI) has surged into overbought territory at 79.64, confirmed by similar extreme readings on the Stochastic RSI and Commodity Channel Index (CCI). Bull/Bear Power (BBP) shows buyers dominating intraday action, but its overbought reading warns of potential exhaustion. The Awesome Oscillator also backs the prevailing bullish tone. Natera climbed $13.70 or 3.51% today after opening with a slight downside gap, now sitting near session highs as intraday volatility stands at 5.16%. The session indicates persistent strength toward the highs in line with momentum signals, although several oscillators flag a potential short-term overbought pause.
Earlier, analysts noted that Natera’s record revenue growth and raised guidance reflected sustained bullish momentum driven by its oncology segment. The latest approval of Signatera in Japan adds a new international growth catalyst, and traders should monitor whether the stock maintains consolidation above the $394.86 support amid heightened volatility.